2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.13B.15 Radiotherapy Combined with Immunotherapy in the Treatment of Brain Metastases from Small Cell Lung Cancer

EP.13B.15 Radiotherapy Combined with Immunotherapy in the Treatment of Brain Metastases from Small Cell Lung Cancer

Pdf Summary

The study titled "Radiotherapy Combined with Immunotherapy in the Treatment of Brain Metastases from Small Cell Lung Cancer" investigates the efficacy of combining brain radiation therapy (BRT) and immunotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC) who have brain metastases. This research addresses a gap in the National Comprehensive Cancer Network (NCCN) guidelines, which lack clear recommendations for treating brain metastases in ES-SCLC patients, despite these metastases significantly worsening prognosis, often resulting in survival of less than three months without treatment.<br /><br />The study examined 187 patients to compare treatments: BRT alone, immunotherapy alone (ICI), and a combination of both (ICIBRT). The results demonstrated that ICIBRT, when used with standard chemotherapy, offered superior outcomes compared to either BRT or ICI alone. Specifically, ICIBRT showed better overall survival (OS), progression-free survival (PFS), and intracranial progression-free survival (iPFS). Median OS was 20.9 months for ICIBRT, compared with 11.6 months for both BRT and ICI alone. Median PFS was 12.6 months for ICIBRT, in contrast to 6.2 months for BRT and 4.8 months for ICI. Furthermore, median iPFS was 14.9 months for ICIBRT, compared to 7.2 months for BRT and 5.3 months for ICI.<br /><br />The study concludes that ICIBRT serves as a more effective first-line therapy for ES-SCLC patients with brain metastases than either BRT or ICI on their own. Additionally, asynchronous ICIBRT may offer advantages over synchronous therapy, suggesting a potential area for further research. These findings underscore the therapeutic promise of integrating immunotherapy with radiotherapy for improving survival outcomes in this challenging patient population.

Asset Subtitle

ShuHao Que

Meta Tag

Speaker ShuHao Que

Topic Small Cell Lung Cancer and Neuroendocrine Tumors

Keywords

Radiotherapy

Immunotherapy

Brain metastases

Small cell lung cancer

ES-SCLC

Survival outcomes

ICIBRT

Progression-free survival

Chemotherapy

NCCN guidelines